The Coalition for Access to Prenatal Screening
The Coalition for Access to Prenatal Screening (CAPS) is a collaborative alliance of five leading genetic testing companies in the U.S. that seeks to improve access to state-of-the-art prenatal screening using cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT) that is easily accessible to all pregnant women who choose to pursue aneuploidy screening, regardless of their risk factors, income, age or geographic location.
NIPT represents a major advance in screening for fetal chromosomal aneuploidies through the analysis of millions of cfDNA fragments in the blood of a pregnant woman. Chromosomal aneuploidies are characterized by an abnormal number of chromosomes, which may cause genetic disorders in a newborn baby, including some birth defects. Prenatal screening for chromosomal aneuploidies using analysis of serum proteins has been the standard of care for decades. However, cfDNA-based NIPT is becoming the preferred method of prenatal screening for many healthcare providers and patients since its introduction to clinical practice in 2011.